BioCentury
ARTICLE | Company News

Report: Hanmi discontinuing lung cancer drug olmutinib

April 13, 2018 11:21 PM UTC

Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) will discontinue development of olmutinib, which is approved in South Korea for lung cancer, the Korea Biomedical Review reported Friday. Hanmi did not respond to inquiries.

In 2016, Boehringer Ingelheim GmbH (Ingelheim, Germany) returned olmutinib's rights to Hanmi after the Korean Ministry of Food and Drug Safety reported three serious skin reactions, including one fatal case, in clinical trials of the product to treat non-small cell lung cancer (NSCLC) (see BioCentury Extra, Sept. 30, 2016)...